Prostate Cancer

Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

Alessandro Sciarra*a, Valeria Panebiancob, Stefano Salcicciaa, Marcello Osimanib, Danilo Lisi b, Mauro Ciccariello b, Roberto Passariello b, Franco Di Silverioa, Vincenzo Gentilea

a Department of Urology, University Sapienza, Rome, Italy
b Department of Radiology, University Sapienza, Rome, Italy

Abstract

Objectives: To assess the accuracy of magnetic resonance (MR) spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced MR (DCEMR) in the depiction of local prostate cancer recurrence in patients with biochemical progression after radical prostatectomy (RP).

Materials and methods: 1H-MRSI and DCEMR were performed in 70 patients at high risk of local recurrence after RP. The population was divided on the basis of the clinical validation of MR results with the use of a transrectal ultrasound biopsy examination in a group of 50 patients (group A) and the prostate-specific antigen (PSA) serum level restitution after external beam radiotherapy, in a group of 20 patients (group B).

Results: In group A, 1H-MRSI analysis alone showed a sensitivity of 84% and a specificity of 88%; the DCEMR analysis alone, a sensitivity of 71% and a specificity of 94%; combined 1HMRSI-DCEMR, a sensitivity of 87% and specificity of 94%. Areas under the receiver operating characteristic (ROC) curve for 1HMRSI, DCEMR, and combined 1HMRSI/DCEMR were 0.942, 0.93, and 0.964, respectively.

In group B, 1HMRSI alone showed a sensitivity of 71% and a specificity of 83%; DCEMR, a sensitivity of 79% and a specificity of 100%; combined 1HMRSI and DCEMR, a sensitivity of 86% and a specificity of 100%. Areas under the ROC curve for each of these groups were 0.81, 0.923, and 0.94, respectively.

Conclusion: Our results show that combined 1H-MRSI and DCMRE is an accurate method to identify local prostate cancer recurrence in patients with biochemical progression after RP.

© 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
1. Introduction

At present, tumor recurrence or progression after radical prostatectomy (RP) is assessed by prostate-specific antigen (PSA) serum level measurements and pathological findings of the tumor [1,2]. In particular, a PSA increase over a threshold of 0.2 ng/ml later than 6–12 mo following RP suggests treatment failure with a high risk of local recurrence [3,4], whereas a PSA increase within a shorter period strongly correlates with the presence of distant metastasis progression [5]. In patients with biochemical failure after RP, a diagnostic imaging procedure is often performed to distinguish between local cancer recurrence and distant spread of disease [6,7]. This information influences further therapeutic decisions. Computed tomography (CT) imaging is not widely used for the detection of local recurrence because of the low accuracy of this technique in the differentiation of post-RP local recurrence from postsurgical scarring [8]. Immunoscintigraphy [9] and carbon11 choline positron emission tomography-computed tomography [10] have been introduced as innovative imaging modalities for the detection of disease relapse, but their role is still incompletely defined. Transrectal ultrasound (TRUS) in combination with a TRUS-guided biopsy of the prostatic fossa is considered the most accurate postprostatectomy method to detect local cancer recurrence [11]. However, in the early phase of relapse, when cancer volume is low, Saleem et al [12] have shown that almost 30% of patients have biopsy-proven local recurrence if serum PSA level is <1 ng/ml and that no positive biopsy was found in patients with PSA <0.5 ng/ml. Other studies have reported that the higher serum PSA level after RP is correlated with a higher positive biopsy rate [13,14].

The efficacy of radiotherapy in the treatment of patients with low-volume local recurrences validates the importance of developing a diagnostic technique to detect early post-RP cancer recurrence [15]. Several studies have shown that MR imaging possesses high-contrast and spatial resolution, and may represent a promising technique for accurate evaluation of patients with biochemical relapse after RP [16]. A large number of studies [17,18] have shown that combined 1H-spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced MR imaging (DCEMR) could represent a powerful tool for the initial detection of prostate cancer, and for the early diagnosis of postoperative recurrence [19–22]. However, to our knowledge, no prior study has evaluated the sensitivity and specificity of 1H-MRSI and DCEMR individually and in combination in the detection of prostate cancer local recurrence after RP. Therefore, the purpose of this study was to perform this analysis in a group of patients with biopsy-proven cancer recurrence and in a second group with reduction in PSA level (>50%) following radiation therapy in whom a TRUS biopsy is difficult to perform because of the low volume of the suspected locoregional cancer.

2. Materials and methods

2.1. Study approval and patient population

The protocol was approved by the local ethics committee and all subjects gave written informed consent before inclusion in the study. Between January 2006 and May 2007, we included in the study 70 consecutive male patients who were at high risk for local cancer recurrence after RP on the basis of the pathological stage and postoperative PSA increase, and who were candidates for external beam radiotherapy. All patients were submitted to RP in the urological department of our university. Patients’ age at the time of diagnosis ranged between 56 and 72 yr (mean, 63.8). Inclusion criteria and clinical information gathered for each patient included a surgical pathological local stage pT3a-b; negative surgical margins; post-RP PSA increase >0.2 ng/ml (Hybritech method) later than 6 mo after surgery (mean, 13 ± 4 mo); no adjuvant or neoadjuvant hormone therapies; negative regional lymph nodes (pN0); and no evidence of distant metastases at CT scan and bone scan performed before RP. A control group (CG) of 10 postprostatectomy patients with no suspicion of recurrence or progression (pT2–pN0–M0 with post-RP PSA levels <0.2 ng/ml) were also evaluated for comparison.

All patients at biochemical progression were also submitted to abdomen-pelvic TC and bone scintigraphy to excluded clinical progression.

2.2. MR equipment and image acquisition protocol

All 80 cases were examined after RP (at PSA progression for the 70 cases at high risk of local recurrence and at 6 mo after surgery for the 10 cases in the CG) with the use of a commercially available 1.5-T scanner (Magnetom Avanto, Siemens Medical Solutions, Erlangen, Germany; gradient strength, 45 mT/m; slew rate, 346 T/m/s; rise time, 400 micro/s; featuring total imaging matrix-TIM® technology), equipped with surface phased array (Body Matrix, Siemens Medical Solutions) and endorectal coil, filled with 70–90 ml of air on the basis of patient tolerance (e-Coil, Medrad, Pittsburgh, PA, USA, combined with Endo-Interface, Siemens Medical Solutions). Morphological imaging of the postprostatectomy fossa was performed by acquiring turbo spin echo (TSE) T2-weighted sequences in the axial, sagittal, and coronal planes, with the use of optimized parameters for a better spatial resolution (repetition time [TR], 5190 ms; echo time [TE], 95 ms; flip angle, 150°; average, 3; field of view (FOV) read, 256 mm; FOV phase, 100; thickness, 3 mm; section gap, 0; matrix, 512 × 512; phase resolution, 100%; bandwidth, 130; scan time, 3.40 min). 1H-MRSI data were acquired by two
expert radiologists (V.P. and M.C.) after a first review of morphological images, with maximizing of the coverage of the selected region of suspect recurrence, whereas reducing the inclusion of surrounding structures (muscles, fat, rectal air, urine). In patients with hypointense areas suspected for disease recurrence on morphological images, the volume of interest (VOI) was focused on these regions; in the control group and in patients with no morphological evidence of disease recurrence, the VOI was focused on the periurethral-perianastomotic region. 1H-MRSI was performed by using a section-selected box drawn closely around the prostate fossa, and a point-resolved spectroscopic sequence was obtained with the use of three-dimensional (3D) chemical shift imaging (CSI) sequence with spectral/spatial pulses optimized for quantitative detection of choline and citrate.

DCEMR images were acquired by using a 3D, fast low-angle shot (FLASH), T1-weighted spoiled gradient-echo sequence (TR, 2.44 ms; TE, 0.9 ms; flip angle, 30°; average, 1; thickness, 4 mm; section gap, 0; section number, 12; matrix, 256 × 256; phase resolution, 100%; band width, 120; TA, 4.40 min) to perform 10 measurements in rapid succession, immediately following completion of an intravenous bolus injection of 0.1 mmol of gadopentetate dimeglumine (Multihance, Bracco Spa, Milano, Italy). Contrast was administered with a power injector (Spectris, Medrad) at 2.5 ml/s and was followed by a 15-ml saline flush. Total acquisition time for dynamic contrast-enhanced images was approximately 5 min (6–10 images per second). The 3D volume was acquired with the same positioning and center as the transverse T2-weighted sequence covering the entire prostate fossa and the periurethral-perianastomotic region. Relative gadolinium chelate concentration curves were calculated.

2.3. MR images and data analysis

All 80 cases were submitted to this MR protocol and, in all cases, MR images were analyzed in consensus by two radiologists (V.P. and M.C.) with long experience in urogenital magnetic resonance imaging (MRI), who used an off-line console (Leonardo, Siemens Medical Solutions, Erlangen, Germany). They were unaware of initial PSA serum levels, prostate specific antigen (PSA) level before therapy, PSA level after therapy, prior history of treatment, TRUS biopsy results, or PSA level after radiation therapy. On the basis of the literature for 1H-MRSI[21,22], each voxel was categorized as follows: no solid tissue/empty prostatic fossa when Cho + Cr/Ci was undetectable; fibrotic/scar tissue when Cho + Cr/Ci < 0.2; residual healthy prostatic gland tissue when Cho + Cr/Ci > 0.2 and < 0.5; probably recurrent prostate cancer tissue when Cho + Cr/Ci > 0.5 and < 1; and definitively recurrent prostate cancer tissue when Cho + Cr/Ci > 1. Follow-
asymmetry, and degree of enhancement. On the basis of prior studies, we considered early nodular enhancement (prior to enhancement of the rest of the prostatic fossa and pelvic muscles) and early washout to be features that were highly indicative of prostate cancer [23].

Area under the receiver operating characteristic curve (AUC) was calculated to assess which DCEMRI cut-off values were optimal for cancer discrimination in the different patients groups. The readers considered DCEMR images unusable if the time score was not calculable owing to technical problems. Individual assessments of 1H-MRSI and DCEMR were evaluated in conjunction with the T2-weighted images.

The third analysis phase was performed after a further 1 wk delay. In that analysis the same radiologists interpreted the cases including all available data (morphological, 1H-MRSI, and dynamic MRI findings) and formulated a definitive diagnosis. In these patients in whom the result of one method was uncertain compared with that of another method, the radiologists considered imaging findings in complex but had to furnish a definitive judgment however.

2.5. Histological examination

All patients were subjected to a TRUS-guided biopsy 5–6 wk after MR imaging of the postprostatectomy fossa, performed with the use of a biplanar 7.5-MHz frequency probe. In patients in whom biochemical relapse emerged, biopsy specimens were taken under TRUS with the use of an 18-G needle loaded in a spring action automatic biopsy device and were fixed overnight in a solution of 10% neutral buffered formalin. TRUS in a control group (CG) 10 patients No PSA progression and negative TRUS, underwent six random guided biopsies of the prostatic fossa: These patients however were included in the second group of our study.

2.6. Statistical analysis and clinical validation

Statistical data analysis was performed with the statistical software MedCalc Software Demo for Windows, version 9.3 (Mariakerke, Belgium). Sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs) of detecting prostate cancer were calculated for the first, second, and third data sets, and receiver operating characteristic (ROC) curves were generated to summarize the data. For the analysis of 1H-MRSI data, a standardized uptake ratio maximum cut-off value of Cho + Cr/Cl > 0.5 was employed, and an area under the AUC was calculated to assess which cut-off value for each dynamic curve parameter (OT, TTP, PE, WSH) could be optimal for cancer detection.

Patients were divided into two groups (Table 1) on the basis of the clinical validation used for MR results. The “gold standard” for local disease presence was ascertained on the basis of one of the following methods: a reliable TRUS-biopsy result from the postprostatectomy fossa (group A), or a reduction in PSA level (>50%) following radiation therapy (group B). The CG was evaluated as a reference. A patient suspected for local recurrence detected with MR imaging was considered to be true-positive when the imaging results correlated with the conclusive histopathological findings. To allow for reasonable differences in morphology between the evaluated imaging and histopathological findings, we considered the histopathologically and imaging-detected tumors to be of comparable size, localization, and number. When this condition was not respected, a patient was considered to be false-positive. Comparisons of these parameters at per-ROI analysis versus those per-patient analysis revealed only minor nonsignificant differences.

**Table 1 – Patient groups**

<table>
<thead>
<tr>
<th>Group</th>
<th>Patients number</th>
<th>PSA serum level at progression after RRP</th>
<th>Maximal transverse dimension of a mass representing local suspected recurrence</th>
<th>Features and standard validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>50 patients (47 with histologic inclusion criteria)</td>
<td>0.9 ng/ml–1.9 ng/ml (mean 1.26 ng/ml)</td>
<td>7.6 mm–19.4 mm (mean 13.3 ± 4.5 mm)</td>
<td>Patients in which a TRUS-biopsy of the post-prostatectomy prostatic fossa was performed as control validation of MR results</td>
</tr>
<tr>
<td>B</td>
<td>20 patients</td>
<td>0.4 mg/ml–1.4 mg/ml (mean 0.8 mg/ml)</td>
<td>5.0 mm–7.2 mm (mean 6 ± 0.5 mm)</td>
<td>Patients in which the PSA level modification after radiation therapy was used as validation of MR results</td>
</tr>
<tr>
<td>CG</td>
<td>10 patients</td>
<td>No PSA progression (&lt;0.2 ng/ml)</td>
<td></td>
<td>Undetectable PSA serum levels (&lt;0.2 ng/ml) who underwent RRP in the same time interval, as control group (CG)</td>
</tr>
</tbody>
</table>

**NOTE:** 1Age range 56 to 72 years (mean 63.8 years), pt3 a-b N0 pathological stage, negative surgical margins, M0; 2 post-RPP PSA increase >0.2 ng/ml from 7 to 20 months after surgery (mean 13 ± 4 months); 3measured on T2-weighted images; 4three patients with uncertain TRUS-biopsy findings excluded from the analysis. CG: control group.

3. Results

Three patients in group A did not have a reliable TRUS biopsy and were therefore excluded from further analysis. In particular, these patients had uncertain TRUS biopsy findings, and their MR images demonstrated abundant postsurgical fibrosis, so the demarcation between postsurgical changes and tumor recurrence could not be made. No patients were excluded from group B and CG.

Table 1 summarizes patient characteristics and clinical findings.

3.1. Group A

In group A, biopsy-proven local recurrences were identified in 31 of 47 (66%) patients evaluated, whereas 16 (34%) had no biopsy evidence for cancer. PSA level at the time of MR imaging ranged from 0.9 to 1.9 ng/ml (mean, 1.26). The maximal

---

Fig. 1 – Images in a patient with prostate-specific antigen progression after radical prostatectomy, suspected for local recurrence (group A). (A) Transverse T2-weighted fast spin-echo (repetition time (TR), 5190 ms; echo time (TE), 95 ms) magnetic resonance (MR) images show intermediate-signal-intensity mass (arrow) in a periurethral location, suspected for local recurrence, with poor depiction of the borders. (B) B' shows positioning of the volume of interest for MR spectroscopic analysis with three-dimensional chemical shift imaging sequences superimposed on T2-weighted images; in (B), voxel analysis curve shows markedly reduced citrate (Ci) signal and increased choline-creatine to citrate ratio (Cho + Cr/Cit >2) in the area with intermediate signal intensity on T2-weighted images. Three-dimensional fast low-angle shot (FLASH) T1-weighted spoiled gradient-echo image (C) shows a well-defined hypervascular lesion (arrows) relative to the surrounding noncancerous tissue, with excellent depiction of the tumor border. In (D), the corresponding MR signal enhancement-time curve shows a significant difference between pelvic muscle enhancement (region of interest [ROI] 1) and the smaller time to peak and higher peak enhancement values of suspected area (ROI 2). Recurrent carcinoma was histologically validated at transrectal ultrasound-guided biopsy.
transverse dimension of a mass representing local recurrence averaged 13.3 ± 4.5 mm (Fig. 1).

The quality of morphological MR examination was good to excellent in all 47 cases (average signal-to-noise ratio, 3). The location of recurrence within the postprostatectomy fossa was perianastomotic in 13 of 31 patients (41%), around the bladder neck in 11 of 31 (35%), within a retained seminal vesicle in 2 of 31 (6%), and at the anterior or lateral surgical margin in 5 of 31 (16%). Morphology was circumferential in 5 of 31 cases, plaque-like in 8 of 31 cases, and nodular in 18 of 31 cases.

In the independent 1H-MRSI analysis of group A cases (Table 2), spectra consistent with recurrence was correctly observed in 26 of 47 patients; 5 of 47 false-negative, 14 of 47 true-negative, and 2 of 47 false-positive results were observed. The independent DCEMR analysis showed 22 of 47 true-positive with 9 of 47 false-negative, 15 of 47 true-negative, and 1 of 47 false-positive cases.

For 1H-MRSI, sensitivity of 84% and specificity of 88% (PPV, 93%; NPV, 74%) were observed. Sensitivity of 71% and specificity of 94% (PPV, 96%; NPV, 63%) were shown for DCEMR (Table 2).

In the combined 1H-MRSI and DCEMR analysis, there were 27 of 47 true-positive, 4 of 47 false-negative, 15 of 47 true-negative, and 1 of 47 false-positive cases. These results yielded a sensitivity of 87% and specificity of 94% (PPV, 96%; NPV, 79%) for the combined 1H-MRSI and DCEMR analysis (Table 2).

The AUCs for 1H-MRSI, DCEMR, and combined 1H-MRSI/DCEMR values were 0.942, 0.931 and 0.964, respectively (standard error [SE], 0.033, 0.036, and 0.026) (Table 3, Fig. 2).

### Table 2 – MR imaging results for localization of prostate cancer

<table>
<thead>
<tr>
<th>Imaging modality</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR spectroscopic imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient group A</td>
<td>84 (26/31)</td>
<td>88 (14/16)</td>
<td>93 (26/28)</td>
<td>74 (14/19)</td>
</tr>
<tr>
<td>Patient group B</td>
<td>71 (10/14)</td>
<td>83 (5/6)</td>
<td>91 (10/11)</td>
<td>56 (5/9)</td>
</tr>
<tr>
<td>Dynamic MR Imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient group A</td>
<td>71 (22/31)</td>
<td>94 (15/16)</td>
<td>96 (22/23)</td>
<td>63 (15/24)</td>
</tr>
<tr>
<td>Patient group B</td>
<td>79 (11/14)</td>
<td>100 (6/6)</td>
<td>100 (11/11)</td>
<td>67 (6/9)</td>
</tr>
<tr>
<td>Evaluation of combined MRSI and dynamic MR imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient group A</td>
<td>87 (27/31)</td>
<td>94 (15/16)</td>
<td>96 (27/28)</td>
<td>79 (15/19)</td>
</tr>
<tr>
<td>Patient group B</td>
<td>86 (12/14)</td>
<td>100 (6/6)</td>
<td>100 (12/12)</td>
<td>75 (6/8)</td>
</tr>
</tbody>
</table>

NOTE: Values are expressed in percentage. Number of patients in brackets.
NPV = negative predictive value, PPV = positive predictive value.

### Table 3 – ROC curves and comparison of results

<table>
<thead>
<tr>
<th></th>
<th>AUC</th>
<th>Standard error</th>
<th>Difference between areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>First group A: curve A (47 patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Spectroscope Evaluation</td>
<td>0.942</td>
<td>0.033</td>
<td></td>
</tr>
<tr>
<td>2. Dynamic Evaluation</td>
<td>0.931</td>
<td>0.036</td>
<td></td>
</tr>
<tr>
<td>3. Combined Spectroscopic and Dynamic Evaluation</td>
<td>0.964</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>First group: pairwise comparison of ROC curves</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Spectroscopic versus 2. Dynamic</td>
<td>0.029</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>1. Spectroscopic versus 3. Combined SP + DY</td>
<td>0.026</td>
<td>0.022</td>
<td></td>
</tr>
<tr>
<td>2. Dynamic versus 3 Combined SP + DY</td>
<td>0.012</td>
<td>0.032</td>
<td></td>
</tr>
<tr>
<td>Second group B: curve B (20 patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Spectroscopic Evaluation</td>
<td>0.81</td>
<td>0.099</td>
<td></td>
</tr>
<tr>
<td>2. Dynamic Evaluation</td>
<td>0.923</td>
<td>0.061</td>
<td></td>
</tr>
<tr>
<td>3. Combined Spectroscopic and Dynamic Evaluation</td>
<td>0.94</td>
<td>0.053</td>
<td></td>
</tr>
<tr>
<td>Second group: pairwise comparison of ROC curves</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Spectroscopic versus 2. Dynamic</td>
<td>0.055</td>
<td>0.113</td>
<td></td>
</tr>
<tr>
<td>1. Spectroscopic versus 3. Combined SP + DY</td>
<td>0.06</td>
<td>0.131</td>
<td></td>
</tr>
<tr>
<td>2. Dynamic versus 3 Combined SP + DY</td>
<td>0.012</td>
<td>0.018</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: ROC = receiver operating characteristic; DY = Only Dynamic evaluation; SP = Only Spectroscopic evaluation; CI = Confidence Interval.
(70%), whereas 6 (30%) had no significant biochemical variations. PSA level at the time of MR imaging ranged from 0.4 to 1.4 ng/ml (mean, 0.8 ng/ml). The mean maximal transverse dimension of a suspected local recurrence was 6 ± 0.5 mm (Fig. 3).

Independent 1H-MRSI showed 10 of 20 true-positive, 4 of 20 false-negative, 5 of 20 true-negative, and 1 of 20 false-positive cases (sensitivity, 71%; specificity, 83%; PPV, 91%; NPV, 56%). Independent DCEMR showed 11 of 20 true-positive, 3 of 20 false-negative, 6 of 20 true-negative, and 0 false-positive cases (sensitivity, 79%; specificity, 100%; PPV, 100%; NPV, 67%). The combined 1H-MRSI/DCEMR showed 12 of 20 true-positive, 2 of 20 false-negative, 6 of 20 true-negative, and 0 false-positive cases (sensitivity, 86%; specificity, 100%; PPV, 100%; NPV, 75%) (Table 2). AUCs were 0.81, 0.923, and 0.94, respectively (SE, 0.099, 0.061, and 0.053) for 1H-MRSI, DCEMR, and combined 1H-MRSI/DCEMR (Table 3, Fig. 2).

3.3. Control group

No morphological signs of suspected recurrence were evident in all cases of the CG. Moreover, in all 10 cases, at 1H-MRSI analysis no spectra consistent with recurrence was observed (Cho + Cr/Ci < 0.5 in all 10 cases), and at DCEMRI no significant enhancement curves after contrast material injection was described.

4. Discussion

Serial PSA measurements after RP represent the usual follow-up approach for the early detection of prostate cancer recurrence. Clinical nomograms based on PSA or postsurgical pathological parameters have been used to predict whether a recurrence is more likely local or metastatic [7]. Several imaging modalities also have been
introduced in the last two decades to support the decision of urologists and oncologists in the therapeutic planning of prostate cancer recurrence: The selection of a technique for prostate cancer recurrence detection should be based on the questions that need to be answered for a particular patient. The imaging protocols are continuously evolving because of changes in clinical care, scientific discoveries, and technological innovations. All three cross-sectional imaging modalities (CT, MR imaging, and US) have been employed in patients with suspected local prostate cancer recurrence, and each have important limitations. TRUS in association with TRUS-guided biopsy is considered the most sensitive modality for the identification of local recurrence [23,24]. It has been shown that TRUS can miss small foci of recurrent prostate cancer at low PSA levels [25], and that the false-negative rate is
15–20% using combined TRUS with prostatic fossa biopsy [26,27]. Leventis et al [28] reported an overall TRUS-guided biopsy detection rate of 41%, and the most consistent achievement of a diagnosis of a local recurrence with TRUS-guided biopsy was in patients with a PSA level higher than 4 ng/ml [28–30]. In our study we separately categorized patients at high risk for local recurrence after RP into two groups: group A, with substantially elevated PSA levels and a feasible TRUS biopsy of the suspected recurrence; and group B, in whom the size of recurrence did not permit a suitable biopsy but all were submitted to radiation therapy. The division into these two groups was established prior to the MR study, and our intention was to separate patients into a first group in whom good accuracy TRUS biopsy results could be expected (group A) and a second group in whom poor TRUS biopsy results may be expected (group B). In our analysis we looked at the accuracy of 1H-MRSI, DCEMR, and combined 1H-MRSI/DCEMR to assess the contribution of each approach to the correct diagnosis. The results obtained in group A showed that each individual assessment and the combined data all performed well: 0.942, 0.931, and 0.964 AUC values, respectively. In comparison, in the more challenging group B, we observed different results from the three assessments: 0.81, 0.923, and 0.94 AUC values, respectively. The lower performance of 1H-MRSI in group B may reflect the problem that the required voxel size for spectroscopic data is larger than that for DCEMR data, and group B patients would be predicted to have smaller volume diseases. Partial volume effects may be predicted to be more problematic with spectroscopy in the setting of small-volume disease. However it is noteworthy that, also in group B, 1H-MRSI provided important data, as evidenced by the larger AUC value in combined 1H-MRSI/DCEMR data over DCEMR data alone. These findings suggest that there may be a higher diagnostic accuracy of combined 1H-MRSI/DCEMR, in particular for patients with a lower increase of PSA levels and small-volume disease [28].

Our sensitivity and specificity values agree with those reported from other studies, such as the Silverman study [30]. In our opinion, our study has not been biased, as in other analyses, with regard to the small number of patients or to the retrospective inclusion of subjects known to be positive for recurrence. However our findings may be biased by the inclusion of subjects with a pT3 surgical staging, reflecting an increased risk for locoregional cancer recurrence.

Further limitations in our study could be represented by voxel size, effect of saturation bands for 1H-MRSI, and 1.5-T field strength. Futterer et al [31] recently demonstrated that 3D CSI at 3-T allows an increase in spatial, temporal, and spectral resolution in the early diagnosis of prostate cancer. In addition, in our analysis the quantification of metabolite levels was relative to other metabolites because absolute quantification has not yet been perfected for the MR spectroscopic method used in the study [17]. We found that metabolite ratio depends on factors that could differ among voxels in the same patient or among patients (eg, the distance of the voxels from the endorectal coil, the magnetic field homogeneity, the T2 relaxation times). It should be recognized that these factors could have introduced bias against 1H-MRSI data for the discrimination between benign/fibrotic tissue and cancer. On the other hand, our study shows that any limitation in 1H-MRSI data may be overcome by combining this information with DCEMR.

Conflicts of Interest

The authors have nothing to disclose.

References

Editorial Comment on: Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

Noboru Hara
Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
harasho@med.niigata-u.ac.jp
noboharasho@par.odn.ne.jp

Despite recent advances in diagnostic and surgical techniques, prostate-specific antigen (PSA)-based recurrence of prostate cancer after radical prostatectomy (RP) has been reported to range between 15% and 20% [1]. For men with prostate cancer indicated for radical treatments, however, RP is expected to remain the therapeutic mainstay for the foreseeable future, because it is the sole window through which we can accurately determine the pathologic condition of the disease. PSA failure is an initial criterion for local recurrence or metastasis in men with prostate...
cancer who have undergone radical treatments. It is frequently difficult to distinguish between these recurrence patterns by PSA-based monitoring alone, but distinguishing these patterns is important for selecting the appropriate salvage option [3]. Accordingly, improvement in localizing the diagnosis for prostate cancer recurrence during an earlier postoperative period is a challenging problem. The present report by Sciarra et al showed that combined dynamic contrast-enhanced magnetic resonance imaging (MRI) and 1H-spectroscopic imaging are promising modalities to identify and visualize recurrent lesions for patients under such situations [2]. To our knowledge, this is the first study that enrolled a statistically sufficient number of patients and demonstrated the practical utility of MRI for the detection of locally recurrent prostate cancer following surgery. Furthermore, the current study took a characteristic and subtle approach by setting double criteria for assessing the usefulness of MRI; one trial group was comprised of cases evaluated by transrectal ultrasound-guided biopsy and the other arm was assessed by the outcome following salvage radiotherapy, thereby overcoming a common limitation in this type of study where the findings largely depend on the biopsy technique [4]. Treatment selection in patients with postprostatectomy recurrence is an issue of general concern [5], and the present findings may influence the approaches of future clinical trials focusing on the management of postoperative prostate cancer recurrence.

References


DOI: 10.1016/j.eururo.2007.12.035
DOI of original article: 10.1016/j.eururo.2007.12.034

Editorial Comment on: Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

Jurgen J. Füttener, Jelle O. Barentsz
Department of Radiology,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
J.Futterer@rad.umcn.nl

Functional magnetic resonance imaging (MRI) techniques are increasingly used in patients with prostate cancer. These techniques include proton MR spectroscopic imaging (MRSI), dynamic contrast-enhanced MRI (DCEMRI), and diffusion-weighted MRI. In recent years, literature data have shown that the combination of these functional imaging techniques represents an adequate tool for localizing the tumor in the untreated prostate [1,2].

Sciarra et al report on the use of DCEMRI and MRSI in the detection of local recurrence in patients after prostatectomy [3]. The study is based on data from a series of 70 patients at a single institution. The authors assessed and compared the accuracies of these functional imaging tools in detecting local recurrence. They concluded that the combination of DCEMRI and MRSI is an accurate method to identify local prostate cancer recurrence with biochemical failure. This combination resulted in 87% sensitivity and 94% specificity.

After radical prostatectomy, patients are generally followed up by means of digital rectal examination and measurements of the prostate-specific antigen level. Because biochemical failure is not equivalent to clinical failure and may represent isolated local recurrence, systemic recurrence, or both, management of these patients is controversial. Local control is usually assessed...
with transrectal ultrasound-guided biopsy [4], but this is invasive and has limited accuracy after radiation. Furthermore, the traditional strategy of waiting until patients develop biochemical or clinical recurrence before initiating salvage therapy has been questioned.

DCEMRI and MRSI after prostatectomy or radiation therapy are clearly options to detect or rule out local recurrence in patients with biochemical failure. The presence or absence of persistent cancer at needle biopsy performed 2 yr after radiation has been established as an important predictor of long-term outcome [5]. Ultimately, MRI could facilitate early detection and might allow for earlier salvage therapy and better long-term outcomes. These functional MRI techniques can also be applied to localize prostate cancer in the untreated prostate. For example, accurate cancer location with regard to the neurovascular bundle is important for the urologist in case of a nerve-sparing radical prostatectomy.

I believe that use of (functional) MRI of the prostate is extremely important in patient management and that urologists should increasingly consider this imaging modality in their decision-making process.

References


DOI: 10.1016/j.euro.2007.12.036
DOI of original article: 10.1016/j.euro.2007.12.034